{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:11:21Z","timestamp":1793052681621,"version":"4.5.0"},"reference-count":34,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2019,12,1]]},"DOI":"10.1001\/jamacardio.2019.4101","type":"journal-article","created":{"date-parts":[[2019,9,28]],"date-time":"2019-09-28T02:49:44Z","timestamp":1569638984000},"page":"1261","source":"Crossref","is-referenced-by-count":104,"title":["Time-Varying Outcomes With the Absorb Bioresorbable Vascular Scaffold During 5-Year Follow-up"],"prefix":"10.1001","volume":"4","author":[{"given":"Gregg W.","family":"Stone","sequence":"first","affiliation":[{"name":"The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York"},{"name":"The Cardiovascular Research Foundation, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kimura","sequence":"additional","affiliation":[{"name":"Kyoto University Hospital, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runlin","family":"Gao","sequence":"additional","affiliation":[{"name":"Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean J.","family":"Kereiakes","sequence":"additional","affiliation":[{"name":"The Christ Hospital, Heart and Vascular Center, Lindner Research Center, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen G.","family":"Ellis","sequence":"additional","affiliation":[{"name":"Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinobu","family":"Onuma","sequence":"additional","affiliation":[{"name":"Erasmus Medical Center, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Chevalier","sequence":"additional","affiliation":[{"name":"Institut Cardiovasculaire Paris Sud, Massy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Simonton","sequence":"additional","affiliation":[{"name":"Abbott Vascular, Santa Clara, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ovidiu","family":"Dressler","sequence":"additional","affiliation":[{"name":"Columbia University Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Crowley","sequence":"additional","affiliation":[{"name":"Columbia University Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziad A.","family":"Ali","sequence":"additional","affiliation":[{"name":"Columbia University Medical Center, New York, New York"},{"name":"the Cardiovascular Research Foundation, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick W.","family":"Serruys","sequence":"additional","affiliation":[{"name":"International Centre for Cardiovascular Health, Imperial College, London, England"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"45","key":"hoi190071r1","doi-asserted-by":"publisher","first-page":"3386","DOI":"10.1093\/eurheartj\/ehw343","article-title":"Ten-year clinical outcomes of first-generation drug-eluting stents: the Sirolimus-Eluting vs. Paclitaxel-Eluting Stents for Coronary Revascularization (SIRTAX) VERY LATE trial.","volume":"37","author":"Yamaji","year":"2016","journal-title":"Eur Heart J"},{"issue":"12","key":"hoi190071r2","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.jcin.2013.07.009","article-title":"5-Year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).","volume":"6","author":"Gada","year":"2013","journal-title":"JACC Cardiovasc Interv"},{"issue":"5","key":"hoi190071r3","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1161\/CIRCINTERVENTIONS.110.958249","article-title":"Very long-term (15 to 20 years) clinical and angiographic outcome after coronary bare metal stent implantation.","volume":"3","author":"Yamaji","year":"2010","journal-title":"Circ Cardiovasc Interv"},{"issue":"1","key":"hoi190071r4","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.amjcard.2017.03.259","article-title":"Incidence and long-term clinical impact of late-acquired stent fracture after sirolimus-eluting stent implantation in narrowed coronary arteries.","volume":"120","author":"Kuramitsu","year":"2017","journal-title":"Am J Cardiol"},{"issue":"9","key":"hoi190071r5","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/j.jcin.2015.02.029","article-title":"Incidence and clinical impact of stent fracture after PROMUS element platinum chromium everolimus-eluting stent implantation.","volume":"8","author":"Kuramitsu","year":"2015","journal-title":"JACC Cardiovasc Interv"},{"issue":"32","key":"hoi190071r6","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1093\/eurheartj\/ehv205","article-title":"Neoatherosclerosis: overview of histopathologic findings and implications for intravascular imaging assessment.","volume":"36","author":"Otsuka","year":"2015","journal-title":"Eur Heart J"},{"issue":"5","key":"hoi190071r7","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1161\/CIRCINTERVENTIONS.112.000248","article-title":"Increased thin-cap neoatheroma and periprocedural myocardial infarction in drug-eluting stent restenosis: multimodality intravascular imaging of drug-eluting and bare-metal stents.","volume":"6","author":"Ali","year":"2013","journal-title":"Circ Cardiovasc Interv"},{"issue":"2","key":"hoi190071r8","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1161\/CIRCULATIONAHA.116.021539","article-title":"Bioresorbable vascular scaffolds for coronary revascularization.","volume":"134","author":"Kereiakes","year":"2016","journal-title":"Circulation"},{"issue":"3","key":"hoi190071r9","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1161\/CIRCINTERVENTIONS.113.000990","article-title":"Long-term safety of an everolimus-eluting bioresorbable vascular scaffold and the cobalt-chromium XIENCE V stent in a porcine coronary artery model.","volume":"7","author":"Otsuka","year":"2014","journal-title":"Circ Cardiovasc Interv"},{"issue":"22","key":"hoi190071r10","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1161\/CIRCULATIONAHA.109.921528","article-title":"Intracoronary optical coherence tomography and histology at 1 month and 2, 3, and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: an attempt to decipher the human optical coherence tomography images in the ABSORB trial.","volume":"122","author":"Onuma","year":"2010","journal-title":"Circulation"},{"issue":"5","key":"hoi190071r11","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1161\/CIRCULATIONAHA.117.031843","article-title":"Three-year outcomes with the absorb bioresorbable scaffold: individual-patient-data meta-analysis from the ABSORB randomized trials.","volume":"137","author":"Ali","year":"2018","journal-title":"Circulation"},{"issue":"13","key":"hoi190071r12","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.4244\/EIJ-D-17-00492","article-title":"Midterm clinical outcomes with everolimus-eluting bioresorbable scaffolds versus everolimus-eluting metallic stents for percutaneous coronary interventions: a meta-analysis of randomised trials.","volume":"13","author":"Cassese","year":"2018","journal-title":"EuroIntervention"},{"issue":"7","key":"hoi190071r13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"issue":"16","key":"hoi190071r14","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1001\/jama.2015.3656","article-title":"Preferred reporting items for systematic review and meta-analyses of individual participant data: the PRISMA-IPD statement.","volume":"313","author":"Stewart","year":"2015","journal-title":"JAMA"},{"issue":"9962","key":"hoi190071r15","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S0140-6736(14)61455-0","article-title":"A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial.","volume":"385","author":"Serruys","year":"2015","journal-title":"Lancet"},{"issue":"47","key":"hoi190071r17","doi-asserted-by":"publisher","first-page":"3332","DOI":"10.1093\/eurheartj\/ehv435","article-title":"A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan.","volume":"36","author":"Kimura","year":"2015","journal-title":"Eur Heart J"},{"issue":"21","key":"hoi190071r18","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1016\/j.jacc.2015.09.054","article-title":"Bioresorbable vascular scaffolds versus metallic stents in patients with coronary artery disease: ABSORB China trial.","volume":"66","author":"Gao","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"hoi190071r19","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1056\/NEJMoa1509038","article-title":"Everolimus-eluting bioresorbable scaffolds for coronary artery disease.","volume":"373","author":"Ellis","year":"2015","journal-title":"N Engl J Med"},{"issue":"23","key":"hoi190071r20","doi-asserted-by":"publisher","first-page":"2852","DOI":"10.1016\/j.jacc.2017.10.010","article-title":"3-Year clinical outcomes with everolimus-eluting bioresorbable coronary scaffolds: the ABSORB III trial.","volume":"70","author":"Kereiakes","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"hoi190071r21","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.jacc.2014.12.017","article-title":"Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds.","volume":"65","author":"Puricel","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"hoi190071r22","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials.","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"10157","key":"hoi190071r23","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1016\/S0140-6736(18)32283-9","article-title":"Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial.","volume":"392","author":"Stone","year":"2018","journal-title":"Lancet"},{"issue":"24","key":"hoi190071r24","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1161\/CIRCULATIONAHA.117.029289","article-title":"Standardized end point definitions for coronary intervention trials: the Academic Research Consortium-2 Consensus Document.","volume":"137","author":"Garcia-Garcia","year":"2018","journal-title":"Circulation"},{"issue":"14","key":"hoi190071r25","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1056\/NEJMsr1203730","article-title":"The prevention and treatment of missing data in clinical trials.","volume":"367","author":"Little","year":"2012","journal-title":"N Engl J Med"},{"issue":"10025","key":"hoi190071r26","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/S0140-6736(15)01039-9","article-title":"1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis.","volume":"387","author":"Stone","year":"2016","journal-title":"Lancet"},{"issue":"10096","key":"hoi190071r27","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S0140-6736(17)31470-8","article-title":"2-Year outcomes with the Absorb bioresorbable scaffold for treatment of coronary artery disease: a systematic review and meta-analysis of seven randomised trials with an individual patient data substudy.","volume":"390","author":"Ali","year":"2017","journal-title":"Lancet"},{"issue":"23","key":"hoi190071r28","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1016\/j.jacc.2017.09.1106","article-title":"Effect of technique on outcomes following bioresorbable vascular scaffold implantation: analysis from the ABSORB trials.","volume":"70","author":"Stone","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"17","key":"hoi190071r29","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/j.jacc.2015.08.863","article-title":"Very late thrombosis after bioresorbable scaffolds: cause for concern?","volume":"66","author":"Stone","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"hoi190071r30","doi-asserted-by":"crossref","DOI":"10.4244\/EIJ-D-19-00324","article-title":"Three-year clinical and two-year multimodality imaging outcomes of a thin-strut sirolimus-eluting bioresorbable vascular scaffold: MeRes-1 trial.","author":"Seth","year":"2019","journal-title":"EuroIntervention"},{"issue":"8","key":"hoi190071r31","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.jacc.2015.12.019","article-title":"Bioresorbable coronary scaffold thrombosis: multicenter comprehensive analysis of clinical presentation, mechanisms, and predictors.","volume":"67","author":"Puricel","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"hoi190071r32","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.4244\/EIJ-D-16-00247","article-title":"Clinical outcomes of a real-world cohort following bioresorbable vascular scaffold implantation utilising an optimised implantation strategy.","volume":"12","author":"Tanaka","year":"2017","journal-title":"EuroIntervention"},{"issue":"17","key":"hoi190071r33","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1016\/j.jacc.2018.02.051","article-title":"Neoatherosclerosis 5 years after bioresorbable vascular scaffold implantation.","volume":"71","author":"Moriyama","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"hoi190071r34","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.jacc.2015.11.060","article-title":"A Polylactide bioresorbable scaffold eluting everolimus for treatment of coronary stenosis: 5-year follow-up.","volume":"67","author":"Serruys","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"hoi190071r16","unstructured":"Serruys PW, Chevalier B; the ABSORB II Investigators. The 5-year clinical outcomes of the ABSORB II trial: first randomized comparison between the Absorb everolimus eluting bioresorbable vascular scaffold and the XIENCE everolimus eluting stent. https:\/\/www.tctmd.com\/slide\/absorb-beyond-3-years-absorb-ii-5-year-data. Accessed July 22, 2019."}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2752439\/jamacardiology_stone_2019_oi_190071.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,18]],"date-time":"2019-12-18T16:01:07Z","timestamp":1576684867000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2752439"}},"subtitle":["A Systematic Meta-analysis and Individual Patient Data Pooled Study"],"short-title":[],"issued":{"date-parts":[[2019,12,1]]},"references-count":34,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2019.4101","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12,1]]}}}